Clinical Trial Update: Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics study of oral ixazomib (MLN9708) in relapsed/refractory multiple myeloma and advanced solid tumors, including participants with normal …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Solid Tumors

Drugs mentioned

• ixazomib (ixazomib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Multiple Myeloma, Advanced Solid Tumors | Phase 1 | Status: COMPLETED | Results posted: 2019-06-10